Signal Transduction
Stem Cells
Signaling Pathways
Product Type
All Products
New Products
Small Molecules
Peptides
Controlled Substances
Toxins
Caged Compounds
Fluorescent Probes
Screening Libraries
Ligand Sets
Other Product Types
Research Area
Cancer
Cardiovascular System
Endocrinology
Immunology
Neuroscience
Pain & Inflammation
Respiratory System
Y 11Cat. No. 4498 |
Price and AvailabilityBy clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy. |
|
Chemical Name: 1-(2-Hydroxyethyl)-3,5,7-triaza-1-azaniatricyclo[3.3.1.13,7]decane bromide |
Biological Activity
Potent inhibitor of focal adhesion kinase (FAK); prevents FAK autophosphorylation at the Y397 site (IC50 ~ 50 nM in an in vitro kinase assay). Displays selectivity for FAK over a panel of other kinases (concentration used in assay = 1 μM). Decreases cell viability in a number of cancer cell lines; blocks colony formation in SW620 and BT474 cell lines.Technical Data
M.Wt:The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
References
Golubovskaya et al (2008) A small molecule inhibitor, 1,2,4,5-benzenetetraamine tetrahydrochloride, targeting the Y397 site of focal adhesion kinase decreases tumor growth. J.Med.Chem. 51 7405. PMID: 18989950.
Golubovskaya et al (2012) A small molecule focal adhesion kinase (FAK) inhibitor, targeting Y397 site: 1-(2-hydroxyethyl) -3, 5, 7-triaza-1-azoniatricyclo [3.3.1.13,7]decane; bromide effectively inhibits FAK autophosphorylation activity and decreases cancer cell viability, clonogenicity and tumor growth in vivo. Carcinogenesis. PMID: 22402131.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: Y 11, supplier, potent, focal, adhesion, kinase, FAK, inhibits, inhibitors, autophosphorylation, selective, Y11
Quick Order
Find multiple products by catalog number
Cancer Research Guide
Request your free copy
Highlights over 350 products for cancer research. Request a copy or view PDF today.
Kinases Product Listing
Highlights over 350 products for kinase research. Request a copy or view PDF today.
Kinase Inhibitor Toolbox
80 Kinase inhibitors
pre-dissolved in DMSO
Some of the most potent
kinase inhibitors all on one plate
Includes many of the latest kinase inhibitors to become commercially available. Covers a wide range of kinase targets including EGFR, MAPK and CDK.
VEGF Pathway & Anti-Angiogenic Therapy
Written by N. Ferrara & Y. Crawford
A summary of antiangiogenic therapies targeting the VEGF pathway and the mechanisms of therapy resistance.
New Products in this Area
Cyclin-dependent kinase inhibitor
GSK2578215APotent, selective LRRK2 inhibitor; brain penetrant
AmlexanoxInhibitor of TBK1 and IKKε; antiallergic agent
PF 05212384Potent and selective dual PI 3-kinase/mTOR inhibitor
PF 03814735Aurora kinase A and B inhibitor
PF 04691502Dual PI 3-K/mTOR inhibitor
TNPInhibitor of IP6K; also inhibits IP3K
ACHPSelective IKKα and IKKβ inhibitor
PD 0332991 isethionatePotent, selective Cdk4/6 inhibitor; brain penetrant
CZC 24832Selective inhibitor of PI 3-Kinase γ
LY 333531 hydrochlorideProtein kinase C inhibitor; selective for β isozymes
PF 06465469Potent inhibitor of interleukin-2 inducible T cell kinase (ITK). Also inhibits BTK
10Z-HymenialdisinePan kinase inhibitor; potently inhibits MEK-1
CP 690550 citratePotent JAK inhibitor
WYE 687 dihydrochloridePotent and selective mTOR inhibitor
N,N-DimethylsphingosineSphingosine kinase inhibitor
PEP 005Protein kinase C activator
CZC 54252 hydrochloridePotent LRRK2 inhibitor; neuroprotective
Bisindolylmaleimide IIPotent PKC inhibitor and nicotinic receptor antagonist
CID 2011756Pan protein kinase D (PKD) inhibitor; cell permeable
20% Discount*
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.